NCT03331367 is a NA clinical trial of Blood draw in Prostate Cancer, sponsored by NYU Langone Health.

Who is sponsoring NCT03331367?

NCT03331367 is sponsored by NYU Langone Health.

What drugs are being tested in NCT03331367?

Interventions in NCT03331367: Blood draw, Urine sample.

What condition does NCT03331367 study?

NCT03331367 studies Prostate Cancer.

Is NCT03331367 still recruiting?

NCT03331367 is currently completed. Last updated 7 August 2020.

Last reviewed 2020-08-07 · How we verify

NCT03331367

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigating and Characterizing the Immune Response to Prostate Cancer

Completed NA Last updated 7 August 2020

What this trial tests

NA trial testing Blood draw in Prostate Cancer in 40 participants. Completed in 25 February 2020.

Timeline

14 September 2017

Primary endpoint
25 February 2020

25 February 2020

Quick facts

Lead sponsor	NYU Langone Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	40
Start date	14 September 2017
Primary completion	25 February 2020
Estimated completion	25 February 2020
Sites	1 location across United States

Drugs / interventions tested

Blood draw — full drug profile →
Urine sample — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

NYU Langone Health — full company profile →

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a clinical study to investigate and characterize the immune response profile to four different prostate cancer treatments (total cryotherapy, focal cryotherapy, Cyberknife SBRT, and radical prostatectomy) in patients with localized prostate cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cryoablation and immunotherapy: an overview of evidence on its synergy.
Aarts BM, Klompenhouwer EG, Rice SL, Imani F, et al · · 2019 · cited 108× · PMID 31111237 · DOI 10.1186/s13244-019-0727-5
Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.
Balázs K, Antal L, Sáfrány G, Lumniczky K. · · 2021 · cited 23× · PMID 33924671 · DOI 10.3390/jpm11040296
Innate Immune System in the Context of Radiation Therapy for Cancer.
Boopathi E, Den RB, Thangavel C. · · 2023 · cited 14× · PMID 37568788 · DOI 10.3390/cancers15153972

Verify or expand the search:

Other trials of Blood draw

Trials testing the same drug.

NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
NCT07252622 — Progesterone Levels and Frozen Embryo Transfer Outcomes · not yet recruiting
NCT07382076 — Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population · active not recruiting
NCT06011824 — A Study of Effect of Megakaryocytes and Platelets in Breast Cancer · completed
NCT05912400 — Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1 · completed

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03331367 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 7 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03331367.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing